Study guide
8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis
ASCP Molecular Biology Technologist MB
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Strategy
1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy
2 Nucleic Acid Chemistry & Molecular Structure
2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation
3 Central Dogma, Genome Organization & Cytogenetics
3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations
4 Biochemical Reagents & Enzymes
4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives
5 Nucleic Acid Isolation & Purification
5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices
6 Nucleic Acid Quantification & Electrophoresis
6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics
7 PCR Principles & Primer Design Optimization
7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting
8 Advanced Amplification Technologies
8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification
9 DNA Sequencing Technologies
9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
10 Hybridization, Blotting & Cytogenetic Assays
10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)
11 Molecular Infectious Disease Diagnostics
11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing
12 Molecular Oncology & Hematopathology
12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease
13 Medical Genetics, Pharmacogenomics & Identity Testing
13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism
14 Quality Assurance, Controls & Method Validation
14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency
15 Laboratory Operations, Safety & Clinical Variant Reporting
15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS
8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis
Key Takeaways Explain This Topic AI
Absolute qPCR quantification utilizes external standard curves generated from serial 10-fold dilutions of calibrated reference standards, plotting quantification cycle (Cq/Ct) versus log10 target copy number.
The slope of a standard curve defines PCR amplification efficiency: an ideal slope of -3.322 represents 100% efficiency (doubling per cycle, E = 1.0), with acceptable clinical diagnostic assay performance falling between -3.10 and -3.58 (90% to 110% efficiency; R² >= 0.990).
Relative quantification via the comparative 2^(-ΔΔCt) (Livak) method measures fold-change in target gene expression relative to an endogenous housekeeping reference gene (e.g., GAPDH, ACTB) and a calibrator sample, strictly assuming equal and near-100% amplification efficiencies.
Post-PCR dissociation melt curve analysis converts the loss of intercalating dye fluorescence during continuous heating into negative first-derivative peaks (-dF/dT vs. T), where the peak apex defines the amplicon melting temperature (Tm) governed by GC content, length, and sequence mismatches.
High-Resolution Melt (HRM) analysis utilizes saturating dyes (EvaGreen, LCGreen) and ultra-precise thermal monitoring (0.01–0.05°C increments) to detect subtle class I–IV single-base mutations, somatic oncogene variants (KRAS, BRAF), and DNA methylation profiles.
Last updated: August 2026
8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis
Quick Summary: Quantitative real-time PCR delivers analytical rigor through mathematical modeling of amplification kinetics during the geometric phase. In absolute quantification , a standard curve generated from serial dilutions of a known reference material relates the Quantification Cycle ( C q C_q C q / C t C_t C t ) to log 10 ( copy number ) \log_{10}(\text{copy number}) lo g 10 ( copy number ) , where an ideal slope of − 3.322 -3.322 − 3.322 indicates 100 % 100\% 100% amplification efficiency ( E = 1.0 E = 1.0 E = 1.0 ) . In relative quantification , the comparative 2 − Δ Δ C t 2^{-\Delta\Delta C_t} 2 − ΔΔ C t (Livak) method computes fold-changes in target gene expression or somatic copy number alterations normalized against an endogenous reference gene (e.g., GAPDH , ACTB ). For sequence validation and genotyping, post-PCR dissociation melt curve analysis and High-Resolution Melt (HRM) profile amplicon thermodynamics ( − d F / d T -dF/dT − d F / d T vs. T T T ), distinguishing specific products from primer-dimers and resolving subtle single-nucleotide variants.
1. Real-Time qPCR Amplification Kinetics & Cycle Threshold ( C t C_t C t ) Determination
A typical real-time qPCR amplification plot transitions through four distinct kinetic phases as reagents are consumed and reaction equilibria shift: qPCR AMPLIFICATION PHASES & THRESHOLD
- Fluorescence (ΔRn)
- ^ (4) Plateau Phase
- | /------------
- | /
- | (3) Linear /
- | Phase /
- | /
- | (2) Exponential /
- | Phase /
- | Threshold Line /
- | - - - - - - - - - - - - - - - - - - -* - - - - - - - - - - - - - - - -
- | /|
- | (1) Ground Phase (Baseline) / |
- | =================================/ |
- +---+---+---+---+---+---+---+---+------+---+---+---+---+---+---+---+---> Cycle Number
- 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34
- ^
- +-- Quantification Cycle (Cq / Ct = 20.5)
- The Four Kinetic Phases of PCR Amplification
Linear Ground Phase (Baseline Cycles, typically 3–15) : Amplicon fluorescence is submerged beneath the background optical noise of the photodetectors. Software establishes the baseline by averaging fluorescence across these early cycles.
Exponential (Geometric) Phase : Reaction components are in vast molar excess, and the DNA polymerase operates at maximum kinetic velocity. Target DNA doubles every cycle ( X n = X 0 ⋅ 2 n X_n = X_0 \cdot 2^n X n = X 0 ⋅ 2 n under 100 % 100\% 100% efficiency). All quantitative calculations MUST be made during this phase .
Linear Phase : Reaction components (dNTPs, primers, active polymerase) become rate-limiting. Amplification slows from exponential accumulation to a linear rate.
Plateau Phase : Reagents are exhausted, the polymerase is thermally inactivated, and high concentrations of amplicon strands outcompete primers for self-annealing. Fluorescence reaches a terminal flat plateau. End-point fluorescence intensity at plateau does NOT correlate with initial template quantity!
Baseline, Threshold & C t C_t C t ( C q C_q C q ) Mechanics
Baseline Correction : Baseline cycles (commonly cycles 3 through 15) define the background optical signal. Subtracting this baseline yields Δ R n \Delta Rn Δ R n .
Fluorescence Threshold ( T h Th T h ) : The threshold line is placed statistically significantly above background noise (typically 10 standard deviations above baseline) within the middle of the exponential geometric phase when plotted on a log 10 \log_{10} lo g 10 fluorescence scale.
Quantification Cycle ( C q C_q C q / C t C_t C t / C p C_p C p ) : The exact fractional cycle number at which the amplification curve crosses the fluorescence threshold. Because C t C_t C t is determined during exponential amplification, C t C_t C t is inversely proportional to the logarithm of the initial target copy number .
2. Absolute Quantification via Standard Curve Analysis
Absolute quantification determines the exact molar concentration or copy number of a target nucleic acid (e.g., clinical viral loads for HIV-1, HCV, HBV, or CMV) by comparing sample C t C_t C t values against an external standard curve . qPCR STANDARD CALIBRATION CURVE
- Quantification Cycle (Ct)
- ^
- 35 | * Standard 1 (10^2 copies, Ct = 33.2)
- 30 | * Standard 2 (10^3 copies, Ct = 29.9)
- 25 | * Standard 3 (10^4 copies, Ct = 26.6)
- 20 | * Standard 4 (10^5 copies, Ct = 23.3)
- 15 | * Standard 5 (10^6 copies, Ct = 20.0)
- +-------+-------+-------+-------+-------+-------+-------+-------+-----> log10 [Starting Copy Number]
- 2 3 4 5 6 7 8
- Regression Equation: Ct = (Slope) · log10(Quantity) + y-Intercept
- Ideal Slope = -3.322 (10-fold dilution shifts Ct by exactly 3.322 cycles)
- Mathematical Derivation of Amplification Efficiency
During exponential PCR, the template accumulation equation is expressed as: N n = N 0 ⋅ ( 1 + E ) n N_n = N_0 \cdot (1 + E)^n N n = N 0 ⋅ ( 1 + E ) n
Where N n N_n N n is the number of amplicon molecules at cycle n n n , N 0 N_0 N 0 is the initial copy number, n n n is the cycle number ( C t C_t C t ), and E E E is the fractional amplification efficiency ( 0.0 ≤ E ≤ 1.0 0.0 \le E \le 1.0 0.0 ≤ E ≤ 1.0 ). At the threshold crossing point, N C t N_{C_t} N C t is a constant value across all reactions: log 10 ( N C t ) = log 10 ( N 0 ) + C t ⋅ log 10 ( 1 + E ) \log_{10}(N_{C_t}) = \log_{10}(N_0) + C_t \cdot \log_{10}(1 + E) lo g 10 ( N C t ) = lo g 10 ( N 0 ) + C t ⋅ lo g 10 ( 1 + E )
Rearranging for C t C_t C t as a function of log 10 ( N 0 ) \log_{10}(N_0) lo g 10 ( N 0 ) : C t = − ( 1 log 10 ( 1 + E ) ) ⋅ log 10 ( N 0 ) + ( log 10 ( N C t ) log 10 ( 1 + E ) ) C_t = -\left(\frac{1}{\log_{10}(1 + E)}\right) \cdot \log_{10}(N_0) + \left(\frac{\log_{10}(N_{C_t})}{\log_{10}(1 + E)}\right) C t = − ( lo g 10 ( 1 + E ) 1 ) ⋅ lo g 10 ( N 0 ) + ( lo g 10 ( 1 + E ) lo g 10 ( N C t ) )
This matches the standard linear regression equation y = m x + b y = mx + b y = m x + b , where: Slope ( m ) = − 1 log 10 ( 1 + E ) \text{Slope } (m) = -\frac{1}{\log_{10}(1 + E)} Slope ( m ) = − lo g 10 ( 1 + E ) 1
Solving for efficiency ( E E E ) and percentage efficiency ( % E \%E % E ): E = 10 − 1 / Slope − 1 E = 10^{-1/\text{Slope}} - 1 E = 1 0 − 1/ Slope − 1 % Efficiency ( % E ) = ( 10 − 1 / Slope − 1 ) × 100 % \%\text{Efficiency } (\%E) = \left(10^{-1/\text{Slope}} - 1\right) \times 100\% % Efficiency ( % E ) = ( 1 0 − 1/ Slope − 1 ) × 100%
Clinical Standard Curve Validation Benchmarks +----------------------------------------------------------------------------------------------------+
- | CLINICAL STANDARD CURVE VALIDATION CRITERIA |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Parameter | Ideal Value | Acceptable Range | Clinical Significance & Diagnostic QC |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Slope (m) | -3.322 | -3.10 to -3.58 | -3.322 corresponds to E = 100% |
- | | | | (1 doubling / cycle; 3.32 Ct/log10) |
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Efficiency (%E) | 100.0% | 90.0% to 110.0% | <90%: PCR inhibition or poor primers; |
- | | | | >110%: Primer-dimers or pipetting error|
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Correlation (R^2) | 1.000 | >= 0.990 | Measures linearity across dynamic range|
- +-------------------+-------------------+-------------------+----------------------------------------+
- | Dynamic Range | >= 6 Logs | >= 5 Logs | Linear range (e.g., 50 to 10^7 IU/mL) |
- +-------------------+-------------------+-------------------+----------------------------------------+
Worked Clinical Calculation Example: Quantitative Viral Load +---------------------------------------------------------------------------------------------------+
- | WORKED CLINICAL VIRAL LOAD CALCULATION |
- +---------------------------------------------------------------------------------------------------+
- | Scenario: A clinical laboratory runs a CMV quantitative real-time PCR assay. |
- | A standard curve generated from 10-fold serial dilutions yields the regression equation: |
- | |
- | Ct = -3.320 · log10(Copies/µL) + 38.50 |
- | R^2 = 0.998 |
- | |
- | A patient plasma DNA extract is tested in duplicate and yields an average Ct of 25.24. |
- | Extraction details: 0.50 mL (500 µL) of plasma was extracted and eluted into 50 µL of buffer. |
- | Exactly 5 µL of eluted DNA was added into the qPCR reaction (Total reaction = 20 µL). |
- | |
- | Step 1: Calculate Amplification Efficiency |
- | %E = (10^(-1 / -3.320) - 1) × 100% = (10^0.3012 - 1) × 100% = 100.1% (Valid!) |
- | |
- | Step 2: Solve for Target Concentration in the qPCR Reaction (Copies/µL) |
- | 25.24 = -3.320 · log10(Copies/µL) + 38.50 |
- | -3.320 · log10(Copies/µL) = 25.24 - 38.50 = -13.26 |
- | log10(Copies/µL) = -13.26 / -3.320 = 3.994 |
- | Copies/µL of reaction = 10^3.994 = 9,862.8 copies/µL of PCR mix |
- | |
- | Step 3: Calculate Total Copies in the Entire Eluate |
- | Reaction contained 5 µL of DNA -> Concentration in eluate = 9,862.8 copies/µL |
- | Total Eluate = 50 µL -> Total Copies = 9,862.8 copies/µL × 50 µL = 493,140 copies |
- | |
- | Step 4: Calculate Viral Load per mL of Original Plasma |
- | Original Plasma Volume = 0.50 mL |
- | Plasma Viral Load = 493,140 copies / 0.50 mL = 986,280 copies/mL (or 5.99 log10 copies/mL) |
- +---------------------------------------------------------------------------------------------------+
3. Relative Quantification: Comparative C t C_t C t ( 2 − Δ Δ C t 2^{-\Delta\Delta C_t} 2 − ΔΔ C t ) & Pfaffl Models
Relative quantification determines the fold-change in expression of a target gene (or somatic copy number alteration) relative to an untreated or normal calibrator sample , normalized against an endogenous reference (housekeeping) gene (e.g., GAPDH , ACTB , B2M , 18S rRNA ). THE COMPARATIVE 2^(-ΔΔCt) (LIVAK) METHOD
- Step 1: Normalize Target to Endogenous Reference in Test Sample
- ΔCt(test) = Ct(target, test) - Ct(reference, test)
- Step 2: Normalize Target to Endogenous Reference in Calibrator Sample
- ΔCt(calibrator) = Ct(target, calibrator) - Ct(reference, calibrator)
- Step 3: Calculate Delta-Delta Ct
- ΔΔCt = ΔCt(test) - ΔCt(calibrator)
- Step 4: Compute Normalized Relative Fold-Change
- Normalized Relative Fold-Change = 2^(-ΔΔCt)
- Essential Assumptions of the Livak ( 2 − Δ Δ C t 2^{-\Delta\Delta C_t} 2 − ΔΔ C t ) Method
Equal Amplification Efficiencies : The amplification efficiency of the target assay and the reference assay must be nearly identical (within 10 % 10\% 10% , meaning ∣ Δ Slope ∣ < 0.1 |\Delta\text{Slope}| < 0.1 ∣Δ Slope ∣ < 0.1 ).
High Efficiency : Both assays must amplify near 100 % 100\% 100% efficiency ( E ≈ 1.0 E \approx 1.0 E ≈ 1.0 ).
Reference Gene Stability : The endogenous control gene expression must remain strictly constant across all experimental conditions, tissues, or disease states.
Worked Clinical Example: Oncogene Amplification +---------------------------------------------------------------------------------------------------+
- | WORKED CLINICAL ONCOGENE AMPLIFICATION CALCULATION |
- +---------------------------------------------------------------------------------------------------+
- | Scenario: A clinical technologist assays HER2 (ERBB2) gene copy number in a breast carcinoma |
- | biopsy (Test Sample) compared to normal diploid control genomic DNA (Calibrator Sample). |
- | The reference gene is the diploid single-copy gene RPP30. |
- | |
- | qPCR Data: |
- | • Biopsy Tumor Sample: Ct(HER2) = 18.20 ; Ct(RPP30) = 24.50 |
- | • Normal Calibrator Sample: Ct(HER2) = 25.10 ; Ct(RPP30) = 25.30 |
- | |
- | Step 1: Compute ΔCt for Tumor Test Sample |
- | ΔCt(tumor) = 18.20 - 24.50 = -6.30 |
- | |
- | Step 2: Compute ΔCt for Normal Calibrator Sample |
- | ΔCt(calibrator) = 25.10 - 25.30 = -0.20 |
- | |
- | Step 3: Compute ΔΔCt |
- | ΔΔCt = ΔCt(tumor) - ΔCt(calibrator) = (-6.30) - (-0.20) = -6.10 |
- | |
- | Step 4: Calculate Normalized Fold-Change in HER2 Gene Copy Number |
- | Fold-Change = 2^(-ΔΔCt) = 2^(-(-6.10)) = 2^6.10 = 68.59-fold increase |
- | |
- | Clinical Interpretation: Extreme HER2 gene amplification (Positive for targeted trastuzumab |
- | therapy). |
- +---------------------------------------------------------------------------------------------------+
- The Pfaffl Efficiency-Corrected Model
When the amplification efficiencies of the target ( E target E_{\text{target}} E target ) and reference ( E ref E_{\text{ref}} E ref ) genes deviate significantly, the standard Livak method introduces substantial mathematical error. In such cases, the Pfaffl model corrects for unequal efficiencies: Relative Expression Ratio = ( E target ) Δ C t , target ( calibrator − test ) ( E ref ) Δ C t , ref ( calibrator − test ) \text{Relative Expression Ratio} = \frac{(E_{\text{target}})^{\Delta C_t, \text{ target}(\text{calibrator} - \text{test})}}{(E_{\text{ref}})^{\Delta C_t, \text{ ref}(\text{calibrator} - \text{test})}} Relative Expression Ratio = ( E ref ) Δ C t , ref ( calibrator − test ) ( E target ) Δ C t , target ( calibrator − test )
Where E = 10 − 1 / Slope E = 10^{-1/\text{Slope}} E = 1 0 − 1/ Slope (e.g., 100 % 100\% 100% efficiency → E = 2.0 \rightarrow E = 2.0 → E = 2.0 ; 90 % 90\% 90% efficiency → E = 1.90 \rightarrow E = 1.90 → E = 1.90 ).
4. Post-PCR Dissociation (Melt Curve) Analysis
When non-specific intercalating dyes (e.g., SYBR Green I) or non-cleaved hybridization probes are used, dissociation (melt curve) analysis is performed immediately following the 40 cycles of PCR amplification to confirm amplicon specificity. DISSOCIATION MELT CURVE DECONVOLUTION
- Raw Fluorescence (F) Negative First Derivative (-dF/dT)
- ^ ^
- | | Specific Target Peak
- | ------- (dsDNA Intact) | (Tm = 84.5°C)
- | \ | /\
- | \ | / \
- | \ (Duplex Melting) | Primer-Dimer / \
- | \ | Peak / \
- | \------- (ssDNA Denatured) | (Tm = 72°C) / \
- +-----------------------------------> T (°C) | /\ / \
- 60 65 70 75 80 85 90 95 +---------/--\------/------------\-------> T (°C)
- 60 65 70 75 80 85 90 95
- Physical Principles & Derivative Plotting
Thermal Protocol : Post-PCR, the reaction is cooled to 60 ∘ C 60^\circ\text{C} 6 0 ∘ C to allow complete amplicon hybridization, then slowly heated to 95 ∘ C 95^\circ\text{C} 9 5 ∘ C (e.g., + 0.1 ∘ C +0.1^\circ\text{C} + 0. 1 ∘ C to + 0.5 ∘ C +0.5^\circ\text{C} + 0. 5 ∘ C per second) while continuously recording green fluorescence ( F F F ).
The Melting Temperature ( T m T_m T m ) : Defined as the temperature at which 50 % 50\% 50% of the double-stranded DNA molecules are dissociated into single strands . At T m T_m T m , the intercalating dye rapidly dissociates, causing a sharp drop in fluorescence.
Negative First Derivative ( − d F / d T -dF/dT − d F / d T vs. T T T ) : Because identifying the inflection point on a sigmoidal raw fluorescence curve is difficult, software plots the negative first derivative of fluorescence with respect to temperature ( − d F / d T -dF/dT − d F / d T ) against temperature ( T T T ). The inflection point transforms into a sharp, prominent melting peak at the exact T m T_m T m .
Factors Determining Amplicon Melting Temperature ( T m T_m T m )
GC Content : Guanine-Cytosine base pairs possess three hydrogen bonds and strong base stacking interactions, requiring higher thermal energy to denature than Adenine-Thymine base pairs (two hydrogen bonds). Higher % G C \%GC % GC elevates T m T_m T m .
Amplicon Length : Longer DNA duplexes contain more total hydrogen bonds, increasing T m T_m T m .
Sequence Composition & Base Stacking : Nearest-neighbor thermodynamic interactions dictate local stability.
Buffer Chemistry & Ionic Strength : Monovalent ( Na + , K + \text{Na}^+, \text{K}^+ Na + , K + ) and divalent ( Mg 2 + \text{Mg}^{2+} Mg 2 + ) cations shield the negative charges on the phosphodiester backbone, stabilizing duplexes and raising T m T_m T m . Denaturants (formamide, DMSO) decrease T m T_m T m .
Base Mismatches : A single nucleotide mismatch creates an internal bubble that destabilizes the duplex, dropping T m T_m T m by 1.0 – 5.0 ∘ C 1.0–5.0^\circ\text{C} 1.0–5. 0 ∘ C .
Diagnostic Deconvolution: Specific Amplicon vs. Primer-Dimers
Specific PCR Product : Typically 100 – 300 bp 100–300\text{ bp} 100–300 bp in length with high GC content, producing a sharp, single, symmetrical melting peak at elevated temperatures ( T m > 80 ∘ C T_m > 80^\circ\text{C} T m > 8 0 ∘ C ).
Primer-Dimers & Non-Specific Artifacts : Consist of short ( 30 – 60 bp 30–60\text{ bp} 30–60 bp ), low-stability duplexes that denature at lower temperatures, producing a broad, low-temperature melting peak ( T m < 75 ∘ C T_m < 75^\circ\text{C} T m < 7 5 ∘ C ).
Multiple Peaks in a Monoplex Assay : Indicates either contamination, non-specific mispriming, primer-dimer formation, or heterozygosity/polymorphic sequence variation.
5. High-Resolution Melt (HRM) Analysis
High-Resolution Melt (HRM) is an ultra-precise post-PCR dissociation technique capable of distinguishing sequence variations differing by only a single base pair (SNVs) across an entire un-sequenced PCR amplicon. +----------------------------------------------------------------------------------------------------+
- | HRM TECHNICAL REQUIREMENTS |
- +------------------------------------+---------------------------------------------------------------+
- | Requirement | Technical Specification & Rationale |
- +------------------------------------+---------------------------------------------------------------+
- | **Saturating Intercalating Dye** | **EvaGreen, LCGreen, SYTO-9, Resolight** |
- | | • Used at high concentrations that saturate all binding sites |
- | | • Zero dye redistribution from melted to un-melted duplexes |
- | | • Non-inhibitory to high-fidelity PCR polymerases |
- +------------------------------------+---------------------------------------------------------------+
- | **Thermal & Optical Instrumentation| • High data acquisition density (>= 25 readings per °C) |
- | | • Ultra-fine thermal ramp rates (0.01°C to 0.05°C per second) |
- | | • High well-to-well thermal uniformity (<= 0.1°C variance) |
- +------------------------------------+---------------------------------------------------------------+
- | **Amplicon Design Criteria** | • Small amplicons (50–150 bp) maximize the thermal impact of |
- | | a single base variation (producing ΔTm of 0.5°C to 1.5°C) |
- | | • Eliminates secondary melting domains |
- +------------------------------------+---------------------------------------------------------------+
- SNP Genotyping Classification by HRM HRM DIFFERENCE PLOT SNP PROFILES
- Difference (ΔFluorescence)
- ^
- | Heterozygote (Altered Curve Shape / Shoulder)
- | /\
- | / \ /---\
- | / \--/ \
- | ------------------------------------------------------------- Baseline (Wild-Type Homozygote)
- | \ /
- | \ /
- | \------/ Mutant Homozygote (Thermal Shift ΔTm)
- +-------------------------------------------------------------------> Temperature (°C)
Class 1 (Base exchange: C/T and G/A) : Large thermal shift ( Δ T m ≈ 0.8 – 1.4 ∘ C \Delta T_m \approx 0.8–1.4^\circ\text{C} Δ T m ≈ 0.8–1. 4 ∘ C ) due to loss of a G-C triple bond replaced by an A-T double bond. Easily resolved.
Class 2 (Base exchange: C/A and G/T) : Moderate thermal shift ( Δ T m ≈ 0.5 – 0.7 ∘ C \Delta T_m \approx 0.5–0.7^\circ\text{C} Δ T m ≈ 0.5–0. 7 ∘ C ).
Class 3 (Base exchange: C/G) : Very small thermal shift ( Δ T m ≈ 0.2 – 0.5 ∘ C \Delta T_m \approx 0.2–0.5^\circ\text{C} Δ T m ≈ 0.2–0. 5 ∘ C ).
Class 4 (Base exchange: A/T) : Ultra-subtle thermal shift ( Δ T m < 0.2 ∘ C \Delta T_m < 0.2^\circ\text{C} Δ T m < 0. 2 ∘ C , often < 0.1 ∘ C <0.1^\circ\text{C} < 0. 1 ∘ C ). Requires highest-grade HRM instrumentation.
Heterozygote Discrimination : Heterozygous samples contain four duplex species post-PCR (two homoduplexes and two destabilized heteroduplexes). The heteroduplexes melt early, altering the overall shape and slope of the melting curve (generating distinctive difference plot curves) rather than simply shifting T m T_m T m .
Clinical Diagnostics Applications of HRM
Somatic Mutation Scanning : Rapid pre-screening of oncogenic hotspots ( KRAS codons 12/13, BRAF V600E, EGFR exons 19/21) prior to targeted Sanger or NGS sequencing.
Methylation-Specific HRM (MS-HRM) : Post-bisulfite PCR where unmethylated cytosines are converted to uracil (amplified as thymine), while methylated cytosines remain cytosine. Methylated amplicons have higher GC content and a significantly higher T m T_m T m ( Δ T m = 5 – 10 ∘ C \Delta T_m = 5–10^\circ\text{C} Δ T m = 5–1 0 ∘ C ) than unmethylated amplicons.